Shots:

• The P-III ASCEND study results involve assessing of Calquence as monothx. (100mg- bid) vs Rituximab + Idelalisib (IdR) or Bendamustine (BR) in 310 patients in a ratio (1:1) with CLL prior treated with 1L therapy
• The P-III ASCEND study results: @16.1mos. improvement in PFS; reduction in risk of disease progression by 69%; @12mos. no diseases progression (88% vs 68%)- no news safety signals are observed
• Calquence is a BTK inhibitor- covalently binding with BTK- inhibiting its activity in B-cell and has received FDA’s accelerated approval in Oct’17 for MCL- prior treated with 1L therapy with its expected regulatory submission in H2’19

Ref: AstraZeneca | Image: AstraZeneca